The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
The inhibition of monoacylglycerol lipase by URB602 showed an anti‐inflammatory and anti‐nociceptive effect in a murine model of acute inflammation
Open accessAbstract
Background and purpose: 2‐arachidonoylglycerol (2‐AG) is an endocannabinoid whose hydrolysis is predominantly catalysed by the enzyme monoacylglycerol lipase (MAGL). The development of MAGL inhibitors could offer an opportunity to investigate the anti‐inflammatory and anti‐nociceptive role of 2‐AG, which have not yet been elucidated. On these bases, URB602, a MAGL inhibitor, was tested in a murine model of inflammation/inflammatory pain. Experimental approach: Acute inflammation was induced by intraplantar injection of λ‐carrageenan into mice. The highest dose to be employed has been selected performing the tetrad assays for cannabimimetic activity in mice. URB602 anti‐inflammatory and anti‐nociceptive efficacy (assessed by plethysmometer and plantar test, respectively) was evaluated both in a preventive regimen (drug administered 30 min before carrageenan) and in a therapeutic regimen (URB602 administered 30 min after carrageenan). To elucidate the cannabinoid receptor involvement, rimonabant and SR144528, CB 1 and CB 2 selective antagonists, respectively, were given 15 min before URB602. Key results: Systemic administration of URB602 elicited a dose‐dependent anti‐oedemigen and anti‐nociceptive effect that was reversed exclusively by the CB 2 receptor antagonist. The efficacy of URB602 persisted also when the compound was administered in a therapeutic regimen, suggesting the ability of URB602 to improve established disease. Conclusions and implications: The present report highlighted the ability of the selective MAGL inhibitor, URB602, to prevent and treat an acute inflammatory disease without producing adverse psychoactive effects. The data presented herein also contributed to clarify the physiological role of 2‐AG in respect to inflammatory reactions, suggesting its protective role in the body. British Journal of Pharmacology(2007)152, 787–794; doi:10.1038/sj.bjp.0707425; published online 13 August 2007
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, inhibition of MAGL, the primary catabolic enzyme of 2-AG (Blankman et al, 2007), attenuates carrageenan-induced, acute paw edema and inflammatory pain (Comelli et al, 2007;Ghosh et al, 2013;Ignatowska-Jankowska et al, 2014).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Comelli et al, 2007
Citations
Cites
Ethical guidelines for investigations of experimental pain in conscious animals.
Zimmermann, M. (1983) · Pain · doi:10.1016/0304-3959(83)90201-4 · Cited by 7,762
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia
Hargreaves, K., Dubner, R. A., Brown, F. J., Flores, C., & Joris, J. L. (1988) · Pain · doi:10.1016/0304-3959(88)90026-7 · Cited by 5,155
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
An endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778
SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor
Rinaldi, M. L., Barth, F., Millan, J., Derocq, J., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., et al. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37266-0 · Cited by 716
Compton, D. M., Rice, K. C., Costa, B., Razdan, R. K., Melvin, L. S., Johnson, M. R., & Martin, B. R. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38122-x · Cited by 459
Self-citationGonsiorek, W., Lunn, C. A., Fan, X., Narula, S. K., Lundell, D. J., & Hipkin, R. W. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26516-0 · Cited by 376
Cited by
Sorted by citations
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Targeting the endocannabinoid system: to enhance or reduce?
Marzo, V. D. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 822
The CB2 receptor and its role as a regulator of inflammation
Turcotte, C., Blanchet, M., Laviolette, M., & Flamand, N. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2300-4 · Cited by 632
Endocannabinoid signaling as a synaptic circuit breaker in neurological disease
Katona, I., & Freund, T. F. (2008) · Nature Medicine · doi:10.1038/nm.f.1869 · Cited by 579
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
Metadata
- Authors
- Comelli, F., Giagnoni, G., Bettoni, I., Colleoni, M., & Costa, B.
- Affiliations
- University of Milano-Bicocca (IT)
- University of Milan (IT)
- Corresponding author
- Costa, B
- ORCID
- Costa, B
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 152
- Issue
- 5
- Pages
- 787-794
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC2190015
- OpenAlex
- W1505609996
- Cited by
- 97
- References
- 34
- Citations by year
- 2026: 2 · 2024: 3 · 2022: 5 · 2021: 5 · 2020: 1 · 2019: 2 · 2018: 9 · 2017: 6 · 2016: 1 · 2015: 6 · 2014: 6 · 2013: 8 · 2012: 8
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- monoacylglycerol lipase inhibition, 2-arachidonoylglycerol, endocannabinoids, acute inflammation, inflammatory pain, carrageenan-induced paw edema, CB2 receptor, antinociceptive effect, anti-inflammatory activity
- MeSH terms
- Rimonabant, Acute Disease, Animals, Biphenyl Compounds, Body Temperature, Camphanes, Carrageenan, Disease Models, Animal, Dose-Response Relationship, Drug, Edema, Hindlimb, Hyperalgesia, Inflammation, Injections, Intraperitoneal, Male, Mice, Inbred C57BL, Monoacylglycerol Lipases, Pain, Pain Measurement, Piperidines, Pyrazoles, Pain Threshold, Receptor, Cannabinoid, CB1, Receptor, Cannabinoid, CB2, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
